CN104755079A - 组合 - Google Patents

组合 Download PDF

Info

Publication number
CN104755079A
CN104755079A CN201380055435.XA CN201380055435A CN104755079A CN 104755079 A CN104755079 A CN 104755079A CN 201380055435 A CN201380055435 A CN 201380055435A CN 104755079 A CN104755079 A CN 104755079A
Authority
CN
China
Prior art keywords
amino
carcinoma
cancer
compound
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380055435.XA
Other languages
English (en)
Chinese (zh)
Inventor
K.R.奥格
V.G.R.佩达雷迪加里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of CN104755079A publication Critical patent/CN104755079A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380055435.XA 2012-10-12 2013-10-10 组合 Pending CN104755079A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261712869P 2012-10-12 2012-10-12
US61/712,869 2012-10-12
US201361833561P 2013-06-11 2013-06-11
US61/833,561 2013-06-11
PCT/US2013/064260 WO2014059095A1 (en) 2012-10-12 2013-10-10 Combinations

Publications (1)

Publication Number Publication Date
CN104755079A true CN104755079A (zh) 2015-07-01

Family

ID=50477878

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380055435.XA Pending CN104755079A (zh) 2012-10-12 2013-10-10 组合

Country Status (11)

Country Link
US (1) US20160263116A1 (enExample)
EP (1) EP2906215A4 (enExample)
JP (1) JP2015533165A (enExample)
KR (1) KR20150067323A (enExample)
CN (1) CN104755079A (enExample)
AU (1) AU2013329199A1 (enExample)
BR (1) BR112015008155A2 (enExample)
CA (1) CA2888094A1 (enExample)
IN (1) IN2015DN02667A (enExample)
RU (1) RU2015117483A (enExample)
WO (1) WO2014059095A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2779975T3 (es) 2014-02-07 2020-08-21 Verastem Inc Métodos y composiciones para tratar el crecimiento celular anormal
GB201510628D0 (en) * 2015-06-17 2015-07-29 Glaxosmithkline Ip No 2 Ltd Novel use
WO2021047783A1 (en) 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer
AU2021253243B2 (en) * 2020-04-08 2024-01-18 Aptabio Therapeutics Inc. Agent for treating contrast-induced acute kidney injury
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011062930A1 (en) * 2009-11-17 2011-05-26 Glaxosmithkline Llc Combination
WO2012045194A1 (en) * 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
WO2012103276A1 (en) * 2011-01-26 2012-08-02 Glaxo Wellcome Manufacturing Pte Ltd Combinations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011062930A1 (en) * 2009-11-17 2011-05-26 Glaxosmithkline Llc Combination
WO2012045194A1 (en) * 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
WO2012103276A1 (en) * 2011-01-26 2012-08-02 Glaxo Wellcome Manufacturing Pte Ltd Combinations

Also Published As

Publication number Publication date
JP2015533165A (ja) 2015-11-19
AU2013329199A1 (en) 2015-04-16
US20160263116A1 (en) 2016-09-15
CA2888094A1 (en) 2014-04-17
RU2015117483A (ru) 2016-12-10
BR112015008155A2 (pt) 2017-07-04
KR20150067323A (ko) 2015-06-17
EP2906215A1 (en) 2015-08-19
IN2015DN02667A (enExample) 2015-09-04
EP2906215A4 (en) 2016-05-18
WO2014059095A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
JP5903433B2 (ja) 癌の治療に有用なｖｅｇｆｒ阻害剤およびｍｅｋ阻害剤の医薬的組み合わせ
TW202131917A (zh) 併用醫藥
US20160263116A1 (en) Combinations
JP5858989B2 (ja) 組合せ
TW202114692A (zh) 一種含有mTOR抑制劑的藥物組合及其應用
CN102770026B (zh) 组合
JP2013526578A (ja) 組合せ
US20180214451A1 (en) Combination
US20130237554A1 (en) Combination
EP2603078A1 (en) Combination
JP2015534987A (ja) 組合せ

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150701

WD01 Invention patent application deemed withdrawn after publication